11/17/2026 | Press release | Distributed by Public on 11/17/2026 20:40
The mid-Atlantic region offers a unique blend of academic, clinical, governmental and industry teams that make it a natural hotbed for biomedical innovation. The recent Cell and Gene Therapy Symposium, led by Children's National and partners, focused on how those substantial resources of expertise and support are being leveraged to develop cutting edge cell and gene therapy treatments for many different pediatric conditions.
What it means
Now in its fourth year, the Cell and Gene Therapy Symposium brings together more than 150 leaders from industry, academia, healthcare and government to explore the latest advances in these treatments.
This year's program highlighted sickle cell disease, patient access, regional innovation, emerging research and gave attendees opportunities to connect with others from across the mid-Atlantic region. Some key topics included:
See the complete list of presenters and topics in the full meeting agenda.
"I'm amazed by the breadth of research and clinical development happening in the mid-Atlantic region, and every year the need for partnership is affirmed," said event organizer Patrick Hanley, PhD, chief and director of the Cellular Therapy Program at Children's National. "Four years from our first symposium, we are no longer just talking about partnerships, we're seeing them in action and I think that will ultimately make a difference for our region, our field, and for patients."
Why it matters
Sickle cell disease is a prime example of a condition that has already been revolutionized by innovations in cell and gene therapy, especially at Children's National. Several parents and patients took center stage at the meeting to share the life-changing nature of curative gene therapy for sickle cell disease.
They, and the care providers who helped them navigate the treatment process, called for expanded access to curative gene therapies through more general inclusion criteria, clear patient education about risks and benefits and strong support for families throughout the decision-making process
Similar themes were echoed during an afternoon session featuring a patient who received CAR T cell therapy and their physician, Jennifer Kanakry, MD, from Medstar Georgetown Hospital. Additionally, the patient and Dr. Kanakry emphasized the need for supportive care, additional financial considerations and the importance of patient experience when developing these therapies, which often require lengthy treatment courses and frequent follow-up visits.
The strides in sickle cell disease and CAR-T are a testament to what is possible. Other sessions featured presentations highlighting ongoing research into treatments for a wide range of other conditions, from viral infections such as COVID-19 to heart failure and persistent, relapsed and refractory childhood cancers.
What's next
Partnership to widen access. Connecting leaders from clinical care, laboratory research, industry and governmental agencies creates a one-of-a-kind opportunity for discussion about removing hurdles to innovation. Peter Marks, MD, PhD, former head of the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), offered important perspective on the role that regulatory agencies like the FDA might play in ensuring these innovative new treatments can benefit as many patients as possible. He highlighted how, in his time at FDA and now in his current role at Eli Lilly, government agencies are working with clinicians, scientists and industry partners to update regulatory pathways and inclusion categories to get these treatments to more patients, more quickly.
Building the talent pipeline. An afternoon discussion with Michael Friedlander, PhD, executive director of the Fralin Biomedical Research Institute at Virginia Tech, and Catherine Bollard, MBChB, MD, senior vice president and chief research officer at Children's National, drew attention to another essential task: The training and engagement of the future workforce across all aspects involved in development, production and delivery of cell and gene therapies. That includes faculty and investigators, as well as those with expertise in manufacturing, regulatory science and clinical translation.
To that end, for the first time, the meeting offered a new opportunity for trainees and early career professionals to submit their research for oral or poster presentations.
The big picture
The discussions at this year's meeting conveyed a strong sense of optimism that the region's strategic partnerships, innovative science and investment in future talent will accelerate the development of next-generation therapies and improve patient outcomes.